UPDATE: RBC Capital Issues Positive Comments on Akebia Therapeutics (AKBA), Believes Shares Could Trade Up $5 to $8 on Data
(Updated - May 5, 2020 9:25 AM EDT)(expanding comment)RBC Capital analyst Kennen MacKay reiterated a Sector Perform rating on Akebia ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)